Treatment of BDNF-Related Disorders Using Laquinimod

Abstract

This application provides for a method of increasing brain-derived neurotrophic factor (BDNF) serum level in a human subject comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to increase BDNF serum level in the human subject. The method can further comprise periodically administering to the subject an amount of a second BDNF-increasing agent. This application also provides for a method for treating a human subject suffering from a BDNF-related disease comprising periodically administering laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. This application additionally provides for use of laquinimod in the manufacture of a medicament for increasing BDNF serum, level in a human subject. This application further provides for a pharmaceutical composition comprising an amount of laquinimod effective for use in increasing BDNF serum level in a human subject. This application also provides for a pharmaceutical preparation comprising an amount of laquinimod and an amount of a second BDNF-increasing agent effective for use in increasing BDNF serum level in a human subject.

What is claimed is: 
     
         1 - 17 . (canceled) 
     
     
         18 . A method for treating a human subject suffering from a BDNF-related disease selected from the group consisting of Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, depressive disorders, anxiety disorders, retinitis pigmentosa, erectile dysfunction, memory disorders, Rett syndrome, bipolar disorder and acute mania consisting essentially of periodically administering an amount of laquinimod or a pharmaceutically acceptable salt thereof in an amount effective to treat the human subject. 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . The method of  claim 18 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof is administered to the human subject once daily. 
     
     
         23 . The method of  claim 18 , wherein the periodic administration continues for at least 3 days. 
     
     
         24 . The method of  claim 18 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.1 mg/day-40.0 mg/day. 
     
     
         25 . The method of  claim 24 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.1 mg/day-0.6 mg/day. 
     
     
         26 . The method of  claim 24 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.6 mg/day. 
     
     
         27 . The method of  claim 18 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof is administered orally. 
     
     
         28 . The method of  claim 18 , wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium. 
     
     
         29 . A method for treating a human subject suffering from Huntington's disease, consisting essentially of periodically administering an amount of laquinimod or a pharmaceutically acceptable salt thereof effective to treat the human subject. 
     
     
         30 . The method of  claim 29 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof is administered to the human subject once daily. 
     
     
         31 . The method of  claim 29 , wherein the periodic administration continues for at least 3 days. 
     
     
         32 . The method of  claim 29 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.1 mg/day-40.0 mg/day. 
     
     
         33 . The method of  claim 32 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.1 mg/day-0.6 mg/day. 
     
     
         34 . The method of  claim 32 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.6 mg/day. 
     
     
         35 . The method of  claim 29 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof is administered orally. 
     
     
         36 . The method of  claim 29 , wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium. 
     
     
         37 . The method of  claim 33 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof is administered orally. 
     
     
         38 . The method of  claim 37 , wherein the pharmaceutically acceptable salt of laquinimod is laquinimod sodium. 
     
     
         39 . A method for treating a human subject suffering from a BDNF-related disease selected from the group consisting of Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, depressive disorders, anxiety disorders, retinitis pigmentosa, erectile dysfunction, memory disorders, Rett syndrome, bipolar disorder and acute mania comprising periodically administering an amount of laquinimod or a pharmaceutically acceptable salt thereof and an amount of a second BDNF-increasing agent selected from the group consisting of riluzole and fluoxetine effective to treat the human subject. 
     
     
         40 . The method of  claim 39 , wherein the amount of laquinimod or pharmaceutically acceptable salt thereof administered is 0.1 mg/day-40.0 mg/day.